The global molecular diagnostics market size is estimated to reach USD 33.08 billion by 2030, expanding at a CAGR of 3.97% from 2025 to 2030, according to a new report by Grand View Research, Inc. The contraction in the market will be due to the decline in demand for molecular testing for COVID-19. However, factors such as the rising geriatric population and increasing demand for technologies such as NGS is expected to drive market growth.
Molecular diagnostics plays an important role in infectious disease testing as they can yield effective and fast results. Hence, the increasing prevalence of hospital-acquired infections & infectious diseases is projected to drive the market over the forecast period. Increasing incidence and awareness regarding genetic disorders is further anticipated to accelerate market growth. The miniaturization of three basic molecular assays-nanobiotechnology, biochips, and microfluidics are expected to increase the accuracy and specificity of diagnostic outcomes, and hence, increase the demand for molecular diagnostic products. These improvements are expected to enhance the availability of PoC molecular diagnostic tests to yield quick and effective test results.
Companies are expanding their product portfolios with the acquisition of smaller companies. For instance, in March 2021, Hologic announced the acquisition of Diagenode-a molecular diagnostic company with a wide range of PCR instruments, facilitating the detection of over 30 bacteria-for USD 159 million. Similarly, in April 2021, F. Hoffmann-La Roche Ltd. acquired GenMark Diagnostics, Inc. at a price of USD 24.05 per share in cash, and it holds around 82.89% of total shares of GenMark Diagnostics. GenMark Diagnostics, Inc. has proprietary technologies, such as eSensor XT-8 and ePlex, which can be utilized in developing tests for infectious diseases, including bloodstream infections.
Key players are enhancing their range of testing options for real-time PCR instruments by increasing R&D activities for the development of kits that target emerging diseases or by entering into agreements with other kit manufacturing companies. These include the introduction of Cobas HPV test assay in Cobas 4800 by Roche Diagnostics. The introduction of tuberculosis testing Xpert assay on GeneXpert platform by Cepheid is an example of such advancement. Such advances are anticipated to drive the global molecular diagnostics market.
Request a free sample copy or view report summary: Molecular Diagnostics Market Report
The reagents segment dominated the market and accounted for a share of 65.44% of the global revenue in 2024. It is expected to maintain its dominance throughout the forecast years owing to its wide application scope in research & clinical settings and increasing adoption of novel tests.
The polymerase chain reaction technology segment accounted for the largest revenue share in 2024. This is attributed to its use in detecting COVID-19 and other infectious diseases.
The infectious diseases segment accounted for the largest revenue share in 2024. The increased usage of molecular, particularly PCR tests, for diagnosing COVID-19 has increased the segment share significantly.
The central laboratories segment dominated the industry in 2024 owing to high procedure volumes for COVID testing and other healthcare indications in central laboratories.
North America dominated the market and accounted for a 40.95% share in 2024. This is attributed to the rising epidemiology of infectious as well as chronic diseases, thus, encouraging companies to introduce novel molecular diagnostic tests, thereby boosting market growth.
Asia Pacific is anticipated to exhibit significant growth from 2025 to 2030 owing to increased market penetration, initiatives of local market players to increase the adoption of novel diagnostic technologies, and high unmet market needs.
Grand View Research has segmented the global molecular diagnostics market based on product, test location, technology, application, and region:
Molecular Diagnostics Product Outlook (Revenue, USD Million, 2018 - 2030)
Instruments
Regards
Others
Molecular Diagnostics Test Location Outlook (Revenue, USD Million, 2018 - 2030)
Point of care
Self-test or OTC
Central laboratories
Molecular Diagnostics Technology Outlook (Revenue, USD Million, 2018 - 2030)
Polymerase chain reaction (PCR)
PCR, by Procedure
Nucleic Acid Extraction
Others
PCR, by Type
Multiplex PCR
Other PCR
PCR, by Product
Instruments
Reagents
Others
In Situ Hybridization (ISH)
Instruments
Reagents
Others
Isothermal Nucleic Acid Amplification Technology (INAAT)
Instruments
Reagents
Others
Chips and Microarrays
Instruments
Reagents
Others
Mass Spectrometry
Instruments
Reagents
Others
Transcription Mediated Amplification (TMA)
Instruments
Reagents
Others
Others
Instruments
Reagents
Others
Molecular Diagnostics Application Outlook (Revenue, USD Million, 2018 - 2030)
Oncology
Breast Cancer
Prostate Cancer
Colorectal Cancer
Cervical
Kidney
Liver
Blood
Lung
Other
Pharmacogenomics
Infectious disease
MRSA
Clostridium difficile
Vancomycin-resistant enterococci
Carbapenem-resistant bacteria testing
Flu
Respiratory syncytial virus (RSV)
Candida
Tuberculosis and drug-resistant TB
Meningitis
Gastro-intestinal panel testing
Chlamydia
Gonorrhea
HIV
Hepatitis C
Hepatitis B
Other Infectious Diseases
Genetic testing
Newborn screening
Predictive and presymptomatic testing
Others
Neurological disease
Cardiovascular disease
Microbiology
Others
Molecular Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Sweden
Denmark
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Molecular Diagnostics Market
BD
BIOMÉRIEUX
Bio-Rad Laboratories, Inc.
Abbott
Agilent Technologies, Inc.
Danaher
Hologic Inc. (Gen Probe)
Illumina, Inc.
Grifols
QIAGEN
F. Hoffmann-La Roche, Ltd.
Siemens Healthineers AG
Sysmex Corporation
"The quality of research they have done for us has been excellent..."